NCT03920852View on ClinicalTrials.gov

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

December 26, 2019

Study Completion Date

December 26, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

Ruxolitinib cream

Ruxolitinib 1.5% cream applied twice daily.

Trial Locations (10)

23220

Clinical Research Partners LLC, Richmond

32819

Pure Skin Dermatology Aesthetics at Accel Research, Orlando

33014

San Marcus Research Clinic, Inc., Miami Lakes

33174

RM Medical Research, INC., Miami

48326

Oakland Hills Dermatology PC, Auburn Hills

91436

Encino Research Center, Encino

92801

Orange County Research Center, Anaheim

97504

Clinical Research Institute of Southern Oregon - Crisor, Medford

02135

Metro Boston Clinical Partners, Brighton

H2K 4L5

Innovaderm Research Inc., Montreal

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT03920852 - A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter